Observing the Efficacy and Safety of Different Drugs Used in Real-world Familial Mediterranean Fever (FMF) Cases

Tongji Hospital12 enrolled

Overview

retrospective observe the efficacy and safety of different drugs used in familial Mediterranean fever (FMF) cases in real-world

Study Type

OBSERVATIONAL

Enrollment

Conditions

Familial Mediterranean Fever (FMF )

Interventions

real word drugsDRUG

real word drugs

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: \- Clinical diagnosis of Familial Mediterranean fever (FMF) patients (Tel Hashomer criteria) Exclusion Criteria: * Have a history of mental illness, or alcohol and drug dependence； * Pregnant, with severe infection, severe cardiac insufficiency, severe liver or kidney dysfunction； * Complicated with tumors, organ transplants, etc. which have significant impact on the immune system or require the use of immunosuppressants.

Locations (1)

Tongji Hospital

Wuhan, Hubei, China

RECRUITING

Outcomes

Primary Outcomes

Clinical responses graded as Patient Global Assessment (PGA ) decrease

The treatment outcome was graded as PGA decrease:in-response, partial response, good response, or clinical remission corresponding to symptomatic improvement \<30%, 30% to 50%, 50% to 70%, or \>70%, respectively. PGA is a subjective measure where patients rate their overall disease activity or health status on a scale like a visual analog scale (VAS).

Time frame: From baseline,4, 8, 12, 24 and week 52

Central Contacts

Yikai Yu

CONTACT

86-027-83665519 yuyikai@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.